American College of Chest Physicians has published new expert panel guidance around the use of low-dose CT.
There is new evidence-based guidance for the use of low-dose CT (LDCT) for lung cancer screening from the American College of Chest Physicians.
In an article published July 13 in CHEST, an expert panel from the College released 16 clinical recommendations based on a review of 75 studies. The new guidelines focus on the benefits, harms, and implementation of LDCT.
“The goal of these guidelines is to assist stakeholders with the development of high-quality screening programs and arm clinical providers with the information necessary to engage at-risk individuals in order to increase the number of screenings,” said lead author Peter Mazzone, M.D., MPH, FCCP. “Outlined in the recommendations is who should be screened and what that screening process should look like from the clinical side. For an individual patient, these guidelines highlight the importance of education to foster informed, value-based decisions about whether to be screened.”
Here is a summary of the 16 recommendations:
As a supplement to these published recommendations, CHEST and Thomas Jefferson University are offering a course dedicated to helping patients decide whether to undergo screening.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.